Innate Pharma S.A. (IPHA)

Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	66.4	70.61	84.23	103.76	136.79
Short-Term Investments	14.37	21.85	17.26	16.08	14.85
Cash & Short-Term Investments	80.77	92.46	101.49	119.84	151.64
Cash Growth	-12.64%	-8.90%	-15.31%	-20.97%	-30.72%
Accounts Receivable	4.97	15.23	3.08	0.85	10.59
Other Receivables	-	31.26	27.94	12.63	3.28
Receivables	4.97	46.49	31.02	13.47	13.87
Prepaid Expenses	-	5.69	4.67	2.58	6.83
Other Current Assets	-	3.37	2.65	2.36	1.11
Total Current Assets	85.74	148.01	139.83	138.26	173.45
Property, Plant & Equipment	5.13	6.32	8.54	10.17	11.69
Long-Term Investments	10.28	9.8	35.12	39.88	38.93
Other Intangible Assets	-	0.42	1.56	44.19	46.29
Long-Term Deferred Tax Assets	-	9.01	8.57	5.03	7.09
Other Long-Term Assets	9.9	10.64	14.25	29.97	29.97
Total Assets	111.06	184.19	207.86	267.5	307.42
Accounts Payable	16.01	8.56	13.66	14.73	20.73
Current Portion of Long-Term Debt	8.71	8.45	1.28	29.94	1.37
Current Portion of Leases	-	0.49	0.82	0.8	0.78
Current Income Taxes Payable	-	7.02	5.98	7.46	8.33
Current Unearned Revenue	8.06	13.51	16.78	19.92	13.13
Other Current Liabilities	0.21	1.61	2.82	7.03	1.16
Total Current Liabilities	32.98	39.64	41.34	79.89	45.49
Long-Term Debt	22.29	30.61	38.93	11.49	14.19
Long-Term Leases	-	0.35	1.22	2.01	2.76
Long-Term Unearned Revenue	43.95	49.65	60.91	58.41	77.53
Long-Term Deferred Tax Liabilities	-	9.01	8.57	5.03	7.09
Other Long-Term Liabilities	0.27	0.6	0.2	0.25	0.22
Total Liabilities	102.23	132.29	153.71	160.06	151.45
Common Stock	4.19	4.04	4.01	3.98	3.95
Additional Paid-In Capital	390.98	384.26	379.64	375.22	372.13
Retained Earnings	-386.36	-336.89	-330.32	-272.21	-220.46
Comprehensive Income & Other	0.03	0.5	0.82	0.46	0.36
Shareholders' Equity	8.83	51.9	54.15	107.44	155.98
Total Liabilities & Equity	111.06	184.19	207.86	267.5	307.42
Total Debt	31	39.89	42.25	44.25	19.09
Net Cash (Debt)	49.78	52.56	59.23	75.59	132.55
Net Cash Growth	-5.30%	-11.26%	-21.63%	-42.98%	-33.77%
Net Cash Per Share	0.61	0.65	0.74	0.95	1.68
Filing Date Shares Outstanding	81.23	80.86	80.19	79.54	78.98
Total Common Shares Outstanding	81.23	80.86	80.19	79.54	78.98
Working Capital	52.76	108.38	98.49	58.37	127.96
Book Value Per Share	0.11	0.64	0.68	1.35	1.97
Tangible Book Value	8.83	51.49	52.6	63.25	109.69
Tangible Book Value Per Share	0.11	0.64	0.66	0.80	1.39

Updated Sep 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q